ASH 2023 | The feasibility of TKI treatment discontinuation in patients with Ph+ ALL
Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, discusses the results of a retrospective real-world study evaluating the feasibility of tyrosine kinase inhibitor (TKI) treatment discontinuation in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Dr Chiaretti reports that of the fourteen patients who discontinued TKI treatment for various reasons, almost all are still experiencing treatment-free remission (TFR), indicating that a TFR is feasible in selected adult patients with Ph+ ALL. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Incyte: Membership on an entity’s Board of Directors or advisory committees; Abbvie: Membership on an entity’s Board of Directors or advisory committees; Gilead: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Membership on an entity’s Board of Directors or advisory committees; Amgen: Membership on an entity’s Board of Directors or advisory committees.
